ROL:NYSERollins, Inc. Analysis
Data as of 2026-09-01 - not real-time
$36.19
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Rollins, Inc. trades at $36.19, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. The last 30 days have lost 17.5%. With RSI at 37.1 the momentum picture is approaching oversold, alongside a bullish MACD signal. Recent trading has carved out support near $35.81 and resistance around $37.86.
On valuation the read is fair — an earnings multiple of 32.9, absent a reliable peer benchmark. The average analyst target implies 26.0% above today's level. Revenue is growing at 7.9% on a 13.6% profit margin. The 2.02% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 5 — moderate. With 30-day volatility of 33.1%, a beta of 0.11 and a maximum drawdown of 45.2%, position sizing matters here. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
The horizons diverge: sell near-term but hold on a long view, at 1/10 conviction over the longer horizon.
On valuation the read is fair — an earnings multiple of 32.9, absent a reliable peer benchmark. The average analyst target implies 26.0% above today's level. Revenue is growing at 7.9% on a 13.6% profit margin. The 2.02% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 5 — moderate. With 30-day volatility of 33.1%, a beta of 0.11 and a maximum drawdown of 45.2%, position sizing matters here. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
The horizons diverge: sell near-term but hold on a long view, at 1/10 conviction over the longer horizon.
Top Market Events
Rollins' 38% six-month slide improved its entry price, but earnings misses, margin pressure and a premium valuation...Seeking Alpha1monRollins: Earnings Growth Recovery Needs More Evidence Rating Downgrade Rollins is downgraded from buy...Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 52.61
- MACD momentum is positive
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 52.61
- Analyst targets imply +26.0% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Analyst targets imply +26.0% versus the current price
- P/E ratio of 32.9
- Return on equity of 37.0%
Key Metrics & Analysis
Financial Health
Revenue Growth7.90%
Profit Margin13.55%
P/E Ratio32.9
ROE37.01%
ROA14.06%
Debt/Equity78.02
P/B Ratio12.2
Op. Cash Flow$647.0M
Free Cash Flow$501.7M
Technical Analysis
TrendBearish
RSI37.1
Support$35.81
Resistance$37.86
MA 20$36.61
MA 50$40.00
MA 200$52.61
MACDBullish
VolumeDecreasing
Fear & Greed Index92.25
Valuation
Fair Value$16.41
Target Price$45.59
Upside/Downside25.97%
GradeFair
TypeGrowth
Dividend Yield2.02%
Risk Assessment
Beta0.11
Volatility33.14%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.